Bemarituzumab (FUT8-KO) is a monoclonal antibody targeting FGFR2b, expressed in CHO cells with a targeted knockout of the fucosyltransferase 8 gene (FUT8). This genetic modification leads to the absence of core fucose in the polysaccharide structure of the Fc domain, significantly enhancing the antibody's antibody-dependent cellular cytotoxicity (ADCC). The lack of fucose results in increased affinity for human Fc??RIIIa, potentially improving therapeutic efficacy. Bemarituzumab (FUT8-KO) is designed for advanced research applications focusing on cancer therapy and the study of FGFR2b-related biological pathways.
Bemarituzumab (FUT8-KO) is a monoclonal antibody targeting FGFR2b, expressed in CHO cells with a targeted knockout of the fucosyltransferase 8 gene (FUT8). This genetic modification leads to the absence of core fucose in the polysaccharide structure of the Fc domain, significantly enhancing the antibody's antibody-dependent cellular cytotoxicity (ADCC). The lack of fucose results in increased affinity for human Fc??RIIIa, potentially improving therapeutic efficacy. Bemarituzumab (FUT8-KO) is designed for advanced research applications focusing on cancer therapy and the study of FGFR2b-related biological pathways.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
